The Mount Kisco Medical Group and the Cancer Treatment and Wellness Cancer Center at Northern Westchester Hospital conduct clinical trials (research studies), for a variety of cancers. The goal of this research is to find better ways to treat cancer that benefit cancer patients now and in the future. Clinical trials test many types of treatment such as new drugs, new approaches to surgery or radiation therapy, new combinations of treatments, or new methods such as gene therapy. They may also be used to study new approaches for the prevention or diagnosis of cancer. All clinical trials have approval of our Institutional Review Board (IRB), a group of people that review the research to protect patient's rights.
Sponsors of research at Mount Kisco Medical Group and The Cancer Treatment and Wellness Cancer Center include the Clinical Trial Support Unit of the National Cancer Institute (CTSU), the Cancer and Leukemia Group B (CALGB) through our affiliation with Massachusetts General Hospital Cancer Center, as well as pharmaceutical companies. The Oncology Research Coordinator collaborates with the members of the cancer team to identify protocols for patients at our institution. Physicians will identify patients and present initial information on the trial. The Coordinator will provide the patient and family with detailed information regarding all aspects of the trial. Anyone considering joining a clinical research trial must be fully informed about the trial details, benefits, and risks. If the patient agrees, informed consent will be obtained. Once patients are enrolled in a clinical trial, the Research Coordinator and Clinical Trials Nurse together with the treating physician provide ongoing assessment and education to both the patient and the family.
If you would like more information about one of the following clinical trials, listed by cancer site, contact Debbie Goldman Isdale, Clinical Trials Coordinator, via e-mail at dgoldman@nwhc.net or by phone at 914-666-1366, our Nurse Coordinator Charlene Wharton by phone at 914-242-1252, the Medical Director of Clinical Trials, Dr. Jonathan Goldberg or one of our other Oncologists Dr. Julie Gold, Dr. Jeffrey Halaas or Dr. Thomas Lester by phone at 914-241-1050.
Breast Cancer:
A Double-Blind Phase III Trial Of Doxorubicin And Cyclophosphamide Followed By Paclitaxel With Bevacizumab Or Placebo In Patients With Lymph Node Positive And High Risk Lymph Node Negative Breast Cancer (E5103).
A Randomized, Multicenter, Phase III Open-Label Study Of The Efficacy And Safety Of Trastuzumab-Mcc-Dm1 Vs. Capecitabine + Lapatinib In Patients With Her2‑Positive Locally Advanced Or Metastatic Breast Cancer Who Have Received Prior Trastuzumab‑Based Therapy (Genentech - Tdm4370g).
Randomized Double-Blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage Her 2/Neu Overexpressed/Amplified Breast Cancer (Wyeth-3004).
ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study: A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer (N063D).
Ovarian Cancer
Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma (GOG 0252).
Colorectal Cancer
Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Advanced Adenocarcinoma of the Colon or Rectum (CALGB 80405)
Kidney Cancer
ASSURE: Adjuvant Sunitinib or Sorafenib for Unfavorable Renal Cell Carcinoma (E2805). Eligible patients will have kidney cancer that has been removed which was greater than 4cm in size with other high risk features.
Lung Cancer or Lung Metastases
A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (≥4cm) – IIIA Non-Small Cell Lung Cancer (E1505).
Phase I/II Study of Stereotactic Radiation Therapy for Inoperable Primary Lung Cancer and Inoperable Lung Metastases. (NWH sponsored trial).
Neuropathy for patients who received Paclitaxel or Oxaliplatin
A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated with Chemotherapy-Induced Peripheral Neuropathy (CALGB 170601).
Multiple Myeloma
A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase III Study of Panobinostat in Combination with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (Novartis - Panorama-1).
